GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zai Lab ZLAB · USD

Health Care · US listing · 🇺🇸 United States

Compare

26.86

+5.42%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Zai Lab

From its filings with the US Securities and Exchange Commission

SEC filings

Zai Lab is based in Shanghai and is incorporated in Cayman Islands. Its shares trade on Nasdaq under the ticker ZLAB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $460.2m and a net loss of $175.5m. At that date it held total assets of $1.17bn and shareholders' equity of $715.5m.

In its own words

We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies to generate a broad pipeline, including multiple commercial products and multiple programs in late-stage clinical development. We have also built an in-house R&D team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights.

We also seek to build and maintain the trust of our stakeholders, including through our Trust for Life strategy, which includes three commitments: improve human health, create better outcomes, and act right now with ethical business practices and strong corporate governance. As part of our corporate strategy, and the actions taken in support of our corporate goals, we will continue to develop and integrate our Trust for Life strategy into our business and operations.

Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
20 Sept 2017
Employees
1,784
Head office
899 HALEI ROAD, SHANGHAI
Incorporated in
E9
Classification
Pharmaceutical Preparations
Filer status
Large accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Zai Lab Ltd focuses on oncology, immunology, neuroscience, and infectious diseases with strong commercial products.
  • Zai Lab has strategic collaborations with NovoCure Ltd. and Pfizer Inc. for innovative treatments.
  • Zai Lab has 1784 employees dedicated to biopharmaceutical research and development.

Weaknesses

  • Zai Lab's headquarters in Pudong may limit access to global markets.
  • Zai Lab's products are limited to specific medical conditions without broader applications.
  • Zai Lab's listing date of 20 September 2017 shows limited market history.

Opportunities

  • Zai Lab can expand its product portfolio in the Health Care sector with new treatments.
  • Zai Lab can leverage collaborations with Amgen Inc. for global market growth.
  • Zai Lab can target the US market for increased commercialization of its products.

Threats

  • Zai Lab faces competition from established biopharmaceutical companies in the Health Care sector.
  • Zai Lab's reliance on specific medical conditions may lead to market saturation.
  • Zai Lab's products are subject to regulatory challenges in the US market.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.